Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $32.5M | $40.4M | $28.8M | $32.4M | $35.8M | $35.0M | $42.0M | $39.6M | $37.9M | $44.5M |
| Revenue growth | — | 24.3% | -28.7% | 12.5% | 10.6% | -2.2% | 19.9% | -5.9% | -4.3% | 17.6% |
| Operating income | -$1.43M | -$4.08M | -$11.2M | -$9.29M | -$6.38M | -$7.68M | -$5.70M | -$9.55M | -$6.43M | -$2.79M |
| Operating margin | -4.4% | -10.1% | -38.8% | -28.7% | -17.8% | -21.9% | -13.6% | -24.2% | -17.0% | -6.3% |
| Net income | -$945K | -$7.98M | -$6.96M | -$3.54M | -$3.34M | -$3.51M | -$5.57M | -$6.28M | -$6.48M | -$2.84M |
| Net margin | -2.9% | -19.8% | -24.2% | -10.9% | -9.3% | -10.0% | -13.3% | -15.9% | -17.1% | -6.4% |
| EPS (diluted) | -$0.06 | -$0.50 | -$0.45 | -$0.23 | -$0.22 | -$0.24 | -$0.38 | -$0.44 | -$0.46 | -$0.19 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $569K | -$558K | $3.11M | $3.06M | $5.42M | $6.34M | $8.45M | $6.09M | -$612K | $4.93M |
| Capital expenditures | $131K | $276K | $456K | $246K | $141K | $104K | $102K | $281K | $66.5K | $97.9K |
| Free cash flow | $439K | -$834K | $2.66M | $2.81M | $5.27M | $6.24M | $8.35M | $5.81M | -$679K | $4.83M |
| Share buybacks | $2.52M | $3.72M | $2.88M | $3.49M | $1.85M | $1.39M | $1.05M | $741K | $579K | $263K |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $34.5M | $45.4M | $27.9M | $28.2M | $24.8M | $27.0M | $19.8M | $18.3M | $18.0M | $11.4M |
| Total assets | $93.4M | $93.2M | $113M | $105M | $96.5M | $84.5M | $92.9M | $81.8M | $75.6M | $76.8M |
| Total liabilities | $20.3M | $29.3M | $57.1M | $53.5M | $49.6M | $41.9M | $57.0M | $52.5M | $53.0M | $52.3M |
| Shareholders' equity | $73.2M | $64.1M | $55.8M | $51.1M | $47.0M | $42.8M | $36.3M | $29.6M | $22.9M | $24.9M |
| Retained earnings | $18.6M | $11.7M | $4.75M | $1.21M | -$2.13M | -$5.64M | -$11.2M | -$17.5M | -$24.0M | -$26.8M |
| Shares (wtd avg diluted) | 16.2M | 15.9M | 15.6M | 15.4M | 15.2M | 14.9M | 14.6M | 14.3M | 14.1M | 14.9M |
Every figure is extracted from CUMBERLAND PHARMACEUTICALS INC’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.